Halozyme Therapeutics, Inc. (HALO)
Halozyme licenses its ENHANZE drug delivery technology to biopharmaceutical companies and sells its own Hylenex and XYOSTED products. It last closed at $95.97 on Nov 17, down 0.55% on the day. HALO last reported earnings on Thu, Nov 5, 2026. The average 12-month price target from 8 analysts is $118.63 (+23.6% from the last close), with a high of $149.00 and a low of $79.00. Analyst consensus is Buy, based on the latest ratings from 8 firms (4 buy, 4 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in HALO, 0% of them bullish and 100% bearish. In the past 30 days there were 4 dark pool prints totaling $6.8M, the largest $3.3M.
Key Stats
Last 12 monthsNot reported for this period.
From HALO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 8 analysts who set a price target on HALO in the past 90 days. The average target is $118.63, with a high of $149.00 and a low of $79.00, compared with the last close of $95.97.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 11 | Morgan Stanley | Downgrade | Hold | $109 |
| Nov 7 | Leerink Partners | Downgrade | Hold | $110 → $117 |
| Nov 6 | Citizens | Target raised | Buy | $93 → $149 |
| Nov 6 | Evercore ISI Group | Maintained | Buy | $125 |
| Nov 6 | Wells Fargo | Target raised | Hold | $95 → $110 |
Technical Analysis
The stock is 22% below its 20 day and 19% below its 50 day average. It is 11% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 23), oversold. The nearest support is the Pivot S1 at $94.93, and the nearest resistance the Pivot R1 at $97.01.
| RSI (14) | 23.39 | Oversold below 30 | Oversold |
| MACD | -5.35 | Below its signal line | Bearish |
| Stochastic | 1.9 | Near the bottom of its range | Oversold |
| ADX (14) | 42.3 | Strong downtrend | |
| Williams %R | -97.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -111.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −25.4% | Change over 10 sessions | Bearish |
| ATR (14) | $4.28 | Typical daily range, 4.5% of price |
| RSI (14) | 48.35 | Middle of its range | Neutral |
| MACD | 8.25 | Below its signal line | Bearish |
| Stochastic | 16.8 | Near the bottom of its range | Oversold |
| ADX (14) | 41.8 | Strong uptrend | |
| Williams %R | -97.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -35.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −10.5% | Change over 10 sessions | Bearish |
| ATR (14) | $8.32 | Typical daily range, 8.7% of price |
What happened before
See how HALO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How HALO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in HALO in the last 90 days.
Dark Pool
30DHALO Institutional Ownership
Full report →- ▲421 buying vs 313 selling
- ▼Held by funds -29.3 pts
- ▲Funds holding +98
- ▲Superinvestors: 4 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 788 | 690 | +14.2% |
| In funds' top 10 | 20 | 10 | +100.0% |
| Held by funds | 121.1% | – | – |
| New / increased | 164 / 257 | 101 / 276 | +11.7% |
| Reduced / sold out | 254 / 59 | 208 / 75 | +10.6% |
| Put/call ratio | 0.62 | 0.91 | −31.8% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HALO is in one of them and how their past HALO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered HALO in an article yet. Here's the latest on the wider market.
HALO Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Sell (partial) | $1K – $15K | Sep 29, 2026 | Oct 12, 2026 | 13 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Mar 9, 2026 | Apr 7, 2026 | 29 d |
| Gilbert CisnerosD · CA | Sell (partial) | $1K – $15K | Mar 24, 2025 | Apr 7, 2025 | 14 d |
| Josh GottheimerD · NJ | Sell (partial) | $1K – $15K | Sep 9, 2024 | Oct 3, 2024 | 24 d |
| Dan GoldmanD · NY | Sell | $15K – $50K | Jul 12, 2023 | Aug 13, 2023 | 32 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Halozyme Therapeutics
Halozyme Therapeutics is a biopharmaceutical company based in San Diego, California. It licenses its ENHANZE drug delivery technology, built on a patented enzyme, to drugmakers that want to deliver injected medicines under the skin instead of through an IV. The company also develops hyperconcentrated drug formulations and auto-injector devices with pharmaceutical partners, and it sells its own Hylenex and XYOSTED products.
- Headquarters
- San Diego, CA
- Founded
- 1998
- Website
- Halozyme.com ↗








